Results 71 to 80 of about 4,852 (207)

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 2, Page 254-263, January 2026.
Hepatitis B immunoglobulins withdrawal in hepatitis B virus mono‐infected liver transplant recipients: An Italian multicentre prospective study. ABSTRACT Background & Aims Despite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside ...
Raffaella Viganò, Alessandro Loglio, Clara Dibenedetto, Paola Carrai, Silvia Martini, Ilaria Lenci, Bianca Magro, Sara Conti, Paolo Angelo Cortesi, Chiara Mazzarelli, Chiara Becchetti, Giovanni Perricone, Monica Cucco, Marco Carbone, Donatella Cocchis, Elisa Farina, Luisa Pasulo, Mauro Viganò, Michele Sagasta, Elisabetta Degasperi, Davide Ghinolfi, Pietro Lampertico, Stefano Fagiuoli, Luca Saverio Belli, on behalf of the INSIGHT‐B study group   +24 more
wiley   +1 more source

IDDF2021-ABS-0077 Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment [PDF]

, 2021
Grace Lai–Hung Wong, Edward Gane, Calvin Pan, Young‐Suk Lim, Scott Fung, Namiki Izumi, Mang Ma, Carol Yee Kwan Chan, S. Shalimar, Marı́a Buti   +9 more
openalex   +1 more source

Intersections of vitamin D deficiency, HIV and chronic liver diseases

HIV Medicine, Volume 27, Issue 1, Page 4-17, January 2026.
Abstract Objectives Despite effective antiretroviral therapy (ART), chronic liver diseases remain a leading cause of morbidity and mortality among people with HIV, with metabolic dysfunction–associated steatotic liver disease (MASLD) now the predominant etiology. Vitamin D deficiency is also highly prevalent in this population.
Francesca Farina, Aurgho Datta, Suzanne N. Morin, Sahar Saeed, Bertrand Lebouche, Giovanni Guaraldi, Salvatore Petta, Giada Sebastiani   +7 more
wiley   +1 more source

Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments

Gastrointestinal Disorders
Introduction: Chronic hepatitis B (CHB) is a significant public health issue worldwide, especially in the Middle East region. Around 8% to 20% of patients with CHB develop cirrhosis, which may progress to hepatocellular carcinoma.
Hannah Beck, Nishaanth Dalavaye, Kalaikshiga Kengadaran, Mosammath Monira Khatun, Ria Hitesh Patel, Taif Al-Rubaye, Laith Alrubaiy   +6 more
doaj   +1 more source

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls

HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.
Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group   +11 more
wiley   +1 more source

A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions

AIDS Research and Therapy
Introduction Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e.
Sonya Krishnan, Marina B. Martinez Rivera, Christopher K. Lippincott, Maunank Shah   +3 more
doaj   +1 more source

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +1 more source

Impact on weight of a Doravirine switch in people living with HIV

HIV Medicine, Volume 27, Issue 1, Page 136-145, January 2026.
Abstract Background and Objective Doravirine is among the first‐line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti‐integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we
Nina Garofoli, Philippe Flandre, Jean‐Paul Vincensini, Quentin Richier, Priscille Couture, Karine Lacombe, Gilles Pialoux, Jean‐Luc Meynard   +7 more
wiley   +1 more source

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

BMC Infectious Diseases, 2019
Background Tenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function.
Bernard Surial, Matthias Cavassini, Alexandra Calmy, Jan Fehr, Marcel Stöckle, Enos Bernasconi, Bianca Roth, Christoph A. Fux, Helen Kovari, Hansjakob Furrer, Andri Rauch, Gilles Wandeler, the Swiss HIV Cohort Study   +12 more
doaj   +1 more source